Indonesia President Joko Widodo received Sinovac Biotech’s first dose of CoronaVac on Wednesday (January 13). Becoming the country’s first person to receive vaccination.
As everyone knows, President Jokowi received a poke at the Presidential Palace in Jakarta. The incident has broadcast live on national television.
There are also some cabinet members present, and they will also be vaccinated on Wednesday.
Widodo said after the meeting:
“This COVID-19 vaccination is essential for us to break the chain of transmission of this coronavirus and provide health, safety and protection for all Indonesians.”
He added, which will also help promote economic growth.
He also reminds Indonesians that even if the vaccine is introduced, they must still continue to abide by the health regulations.
On Monday, Indonesia has approved the use of the Sinovac vaccine for the first time outside of China. It is the country’s mid-term data from a late-stage clinical trial showed that its effective rate was 65.3%.
Moreover, Sinovac’s CoronaVac uses killed virus particles to expose the body’s immune system to the virus. It needs two doses to be effective.
Not only that, with the sting of Mr. Widodo, Indonesia’s vaccination program has officially begun.
Starting this week, an estimated 1.48 million health workers will be vaccinated. It is expecting that more than 560,000 people will get vaccinate in January. The remaining 9 million people will get vaccinate in February.
It has followed by 17.4 million public officials in high-risk categories.
Indonesia, the worst-hit country by Covid-19 in Southeast Asia
Health Minister Budi Gunadi Sadikin stated in Parliament on Tuesday that from April. 21.5 million elderly people will get vaccinate with Pfizer-BioNTech and AstraZeneca, and the workers from 18 to 59 years old.
Indonesia has more than 840,000 confirmed COVID-19 cases and 24,500 deaths, making it the worst-hit country in Southeast Asia.
To date, the country has received more than 300 million doses of vaccines, including at least 125 million doses from Sinovac, 50 million doses from Pfizer-BioNTech and AstraZeneca, 54 million doses from COVAX and 30 million doses from Novavax.
Furthermore, its goal is to vaccinate 180 million people out of more than 260 million people in order to achieve cattle immunity.